There will be a second straight week with a calendar chalk-full of IPOs.
Six IPOs were on this week’s schedule as of Friday and another five launched this morning.
Debuting Wednesday (9/23)
Bentley Systems, Inc. (BSY) — Their mission is to provide innovative software to advance the design, construction, and operations of the world’s infrastructure—sustaining both the global economy and environment, for improved quality of life.
Corsair Gaming, Inc. (CRSR) — They are a leading global provider and innovator of high-performance gear for gamers and content creators.
GoodRx Holdings, Inc. (GDRX) — They are building the leading, consumer-focused digital healthcare platform in the United States.
Debuting Thursday (9/24)
Taysha Gene Therapies, Inc. (TSHA) — They are a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system in both rare and large patient populations.
Debuting Friday (9/25)
Graybug Vision, Inc. (GRAY) — They are a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve.
Hygo Energy Transition Ltd. (HYGO) — They provide integrated downstream LNG solutions to underserved markets by delivering low cost, environmentally sound energy alternatives to consumers around the world.
Laird Superfood, Inc. (LSF) — Laird Superfood is an emerging consumer products platform focused on manufacturing and marketing highly differentiated plant-based and functional foods.
Orphazyme A/S (ORPH) – They are a late-stage biopharmaceutical company harnessing the amplification of Heat Shock Proteins, or HSPs, in order to develop and commercialize novel therapeutics for the treatment of neurodegenerative orphan diseases. Note: Their ordinary shares are listed on Nasdaq Copenhagen A/S, or Nasdaq Copenhagen, under the symbol “ORPHA.”
PMV Pharmaceuticals, Inc (PMVP) — They are a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutations. p53 is a well-defined tumor suppressor protein known as the “guardian of the genome,” and normal, or wild-type, p53 has the ability to eliminate cancer cells.
Prelude Therapeutics Incorporated (PRLD) — They are a clinical-stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet need.
VIA optronics AG (VIAO) –They are a leading provider of enhanced display solutions for multiple end-markets in which superior functionality or durability is a critical differentiating factor.
For IPO Boutique Research, Ratings and Commentary on all traditional IPO offerings (not direct listings), try us out: http://www.ipoboutique.com/blog/register/
IPO Boutique: Indicate with Confidence.
English
Arabic
Chinese (Simplified)
Dutch
French
German
Italian
Portuguese
Russian
Spanish